Related Experiment Video

Updated: Aug 9, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Continuous subcutaneous insulin infusion pump treatment in children with type 1 diabetes mellitus

Raphael Liberatore1, Kusiel Perlman, Jennifer Buccino

  • 1Division of Endocrinology, Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Canada.

Journal of Pediatric Endocrinology & Metabolism : JPEM
|April 2, 2004
PubMed

Insights

Insulin pump therapy for type 1 diabetes in youth showed significant improvements in HbA1c and body mass index. Long-term use correlated with sustained glycemic control, benefiting pediatric patients.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Technology

Background:

  • Type 1 diabetes mellitus (T1DM) management in children and adolescents presents unique challenges.
  • Insulin pump therapy (IPT) is an increasingly common treatment modality for T1DM.
  • Optimizing IPT outcomes requires understanding its long-term effects in pediatric populations.

Purpose of the Study:

  • To evaluate the impact of insulin pump use on glycemic control (HbA1c), body mass index (BMI), and insulin dosage in children and adolescents with T1DM.
  • To assess the correlation between baseline and follow-up HbA1c levels after initiating IPT.

Main Methods:

  • Retrospective review of medical charts from 73 pediatric patients with T1DM using IPT for over 6 months.
  • Data collection included HbA1c, BMI, and total daily insulin dose at the start of IPT and at 6-30 months follow-up.
  • Statistical analysis to determine significant changes and correlations.

Main Results:

  • Significant reductions in HbA1c by -0.8% were observed.
  • A statistically significant increase in body mass index (BMI) of +1.45 kg/m2 was noted.
  • Total daily insulin dose decreased by -0.23 U/kg/day.
  • A strong positive correlation was found between HbA1c levels before and after 6-30 months of IPT.

Conclusions:

  • Insulin pump therapy is associated with improved glycemic control in pediatric patients with T1DM.
  • IPT may lead to changes in body mass index and insulin requirements.
  • Sustained glycemic control is achievable with long-term insulin pump use in this population.

More Related Videos

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery06:03

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery

Published on: September 30, 2021

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...